{
    "label": "Is this request for initiation or continuation of therapy with Wegovy™ (semaglutide)?",
    "node_type": "fieldset",
    "children": [
        {
            "label": "Start of therapy",
            "outcome": "Initial Authorization for Wegovy™ (semaglutide) may be granted for 6 months when the criteria are met",
            "node_type": "radio",
            "node_value": false,
            "children": [
                {
                    "label": "Body mass index (BMI) meets either of the requirements:",
                    "node_type": "checkbox",
                    "node_value": false,
                    "children": [
                        {
                            "label": "BMI ≥ 30, if no applicable risk factors",
                            "node_type": "checkbox",
                            "node_value": false
                        },
                        {
                            "label": "BMI ≥ 27 with two or more of the following risk factors: coronary heart disease, dyslipidemia, hypertension, sleep apnea, type II diabetes",
                            "node_type": "checkbox",
                            "node_value": false
                        },
                        {
                            "label": "Body weight above 60 kg and an initial BMI corresponding to 30 kg/m² for adults (obese) by international cut-offs (excluding Saxenda® in pediatric patients 12 years of age and older)",
                            "node_type": "checkbox",
                            "node_value": false
                        }
                    ]
                },
                {
                    "label": "Wegovy only covered for members 12 years of age or older",
                    "node_type": "checkbox",
                    "node_value": false
                },
                {
                    "label": "No contraindications to use",
                    "node_type": "checkbox",
                    "node_value": false
                },
                {
                    "label": "No malabsorption syndromes, cholestasis, pregnancy, and/or lactation",
                    "node_type": "checkbox",
                    "node_value": false
                },
                {
                    "label": "No history of an eating disorder (for example, anorexia, bulimia)",
                    "node_type": "checkbox",
                    "node_value": false
                },
                {
                    "label": "Previous failure of a weight loss treatment plan (e.g., nutritional counseling, exercise regimen, calorie/fat-restricted diet) in the past six months and will continue to follow as part of the treatment plan",
                    "node_type": "checkbox",
                    "node_value": false
                },
                {
                    "label": "Current medical status including nutritional or dietetic assessment",
                    "node_type": "checkbox",
                    "node_value": false
                },
                {
                    "label": "Current therapy for all medical conditions (including obesity), identifying specific treatments including medications",
                    "node_type": "checkbox",
                    "node_value": false
                },
                {
                    "label": "Current accurate height and weight measurements",
                    "node_type": "checkbox",
                    "node_value": false
                },
                {
                    "label": "No chronic opioid use concurrently with Contrave®",
                    "node_type": "checkbox",
                    "node_value": false
                },
                {
                    "label": "Member not concurrently on Victoza or Ozempic or other GLP-1 inhibitors (excluding Saxenda®)",
                    "node_type": "checkbox",
                    "node_value": false
                }
            ]
        },
        {
            "label": "Continuation of therapy",
            "outcome": "Reauthorization for Wegovy™ (semaglutide) may be granted for an additional 6-month PA when the criteria are met",
            "node_type": "radio",
            "node_value": false,
            "children": [
                {
                    "label": "The member achieves a weight loss of at least 5% of baseline weight",
                    "node_type": "checkbox",
                    "node_value": false
                }
            ]
        }
    ]
}